Boston Scientific (BSX) Q3 FY26 earnings call

A call dominated by a guidance reset: a cyber incident exposed an underlying cycle turn in the two franchises that drove 2023-25 growth, with management now framing 2027 as the trough and 2028-29 recovery dependent on launches that have already slipped. Credibility on forecasting and pipeline timing is the central debate; restructuring and cost discipline are the offsets.